cubeRandom

Antiestrogen resistance

Amplifications of FGFR1 (left) and CCND1 (right) are enriched in biopsies from letrozole-resistant breast cancers.

cubeRandom

Drug-resistant mutations

The HER2 T798I “gatekeeper” mutation mediates resistance to the HER2 inhibitor neratinib, but not afatinib.

cubeRandom

High-throughput screening

A kinome screen identifies FGFR1 as a mediator of resistance to the combination of an antiestrogen and CDK4/6 inhibitor.

cubeRandom

Targetable alterations

Next-gen sequencing of residual triple-negative breast cancers after neoadjuvant chemotherapy reveals targetable alterations in the residual tumors.

Research

The Arteaga laboratory has a longstanding interest in understanding the molecular pathways that drive breast cancer progression and influence response to therapies.

Read More

About Us

The Arteaga laboratory is located in the Harold C. Simmons Comprehensive Cancer Center, on the fifth floor of the NB building on UTSW's North Campus.

Read More

Meet the Lab